Sentinel lymph node biopsy for cutaneous squamous cell carcinoma: valuable or not valuable?

Genders, Roel E.; Bavinck, Jan Nico Bouwes

doi:10.1111/bjd.13601

Cited by 5 publications

(1 citation statement)

References 11 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 The present study demonstrated slightly higher survival rates, although the outcome remained poor (5-year survival rate of 56%). Many previous studies have investigated the applicability of SLNB for cSCC, [8][9][10][11][12][13][14][15] although there was no consensus that SLNB led to an obvious improvement in prognosis.…”

Section: Discussionmentioning

confidence: 99%

Availability of sentinel lymph node biopsy for cutaneous squamous cell carcinoma

Maruyama

Tanaka

Fujisawa

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma is the second common cutaneous cancer, especially in the elderly. Sentinel lymph node biopsy is generally performed in breast cancers and cutaneous melanomas to detect occult nodal metastases. The benefit of sentinel lymph node biopsy in improving cutaneous squamous cell carcinoma prognosis is doubtful. One hundred and sixty-nine patients who underwent treatment for cutaneous squamous cell carcinoma between 2004 and 2015, and who were followed up for at least 6 months or developed metastases within the follow-up period were included. Forty-nine patients underwent sentinel lymph node biopsy, whereas 120 patients did not, including 13 who exhibited clinical lymph node metastases before treatment. Of these 49 patients, nine (18.4%) presented with sentinel lymph node metastasis, which occurred after treatment in three (6.1%) of them (false-negative). Among the 107 patients who did not undergo lymph node biopsy, 12 (11.2%) developed post-treatment metastases. The metastasis-free and disease-specific survival rates were not significantly different in those who did or did not undergo sentinel lymph node biopsy. Patients with clinical lymph node metastases had a higher risk compared with those without. Patients with T2-T4 tumors had a higher risk compared with those with T1 tumors. When selecting for those with T2 tumors or greater, the same lack of relationship was observed. In conclusion, in this small retrospective cohort, in patients with cutaneous squamous cell carcinoma, there were no significant differences in metastasis-free and disease-specific survival rates between those who did or did not undergo sentinel lymph node biopsy, regardless of T staging.

show abstract